HD Insights: Volume 8

HD Insights: Volume 8

Meet the Compound: Olesoxime (TRO19622)

September 1st, 2014 rtullio Manufacturer: Trophos, S.A. Molecular Formula: C27H45NO Molecular Weight: 400 g/mol Mechanism of Action: Olesoxime is a cholesterol-like compound that exhibits neuroprotective properties. Preclinical studies suggest that olesoxime can promote myelination1 and decrease mitochondrial membrane fluidity in cell and animal models of HD.2   Mitochondrial abnormalities and demyelination are both known features of the pathology of
+ Read More

Research Round-Up

September 1st, 2014 rtullio By: Lise Munsie, PhD In the clinic… The globus pallidus (GP) is thought to be involved in cognitive processes controlling actions, and thus is a possible target for deep brain stimulation (DBS) in HD patients. Beste and colleagues1 report a case control study of patients who received GPDBS, and measured patients’ error monitoring processing, an
+ Read More

Editor’s Letter

September 1st, 2014 rtullio Welcome to the 8th edition of HD Insights, released at the 8th European Huntington Disease Network Plenary Meeting in Barcelona, Spain. We are grateful to the Huntington Study Group (HSG), our sponsors, and our more than 1500 subscribers for their continuing support of our mission. HD Insights relies on the support of firms dedicated to
+ Read More

Repair-HD

September 1st, 2014 rtullio Human pluripotent stem cell differentiation, safety, and preparation for therapeutic transplantation in HD By: Christiane Dascher-Nadel, Anne Rosser, Stephen Dunnett European researchers are taking on the complex task of exploring cell replacement therapy in HD over the next four years, in a project called Repair-HD. Repair-HD brings together an innovative and unique combination of expertise
+ Read More

HD Highlights of the 18th International Congress of Parkinson’s Disease and Movement Disorders

September 1st, 2014 rtullio By: Meredith A. Achey, BM The June 2014 MDS Congress held in Stockholm, Sweden, focused on emerging and experimental therapies for movement disorders. Novel imaging techniques, biomarkers, and models for HD progression and promising cell-based therapies emerged as particular highlights of the Congress’s sessions on HD. Presentations on new markers and models gave a glimpse
+ Read More

Largest HD Clinical Trial Halted

September 1st, 2014 rtullio Coenzyme Q10 “very unlikely” to show significant benefit in HD in 2CARE study The largest randomized, controlled trial ever conducted in HD has been halted for futility. On August 9, 2014, the Huntington Study Group (HSG) reported that the ongoing 2CARE study, a phase 3 trial of Coenzyme Q10 (CoQ10) in HD (see HD Insights
+ Read More

Meet the Investigator

September 1st, 2014 rtullio VITAL SIGNS NAME: Hoa Nguyen, M.D CURRENT POSITION: Head of the Huntington Disease Working Group and Head of Cancer Genetics at the Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany EDUCATION: MD, Hannover Medical School, Hannover, Germany; research at Emory University, Atlanta, Georgia, USA, and McGill University, Montréal, Québec, Canada HOBBIES:
+ Read More

Animal Models of HD

September 1st, 2014 rtullio A critical tool in the quest for treatments By: Mahmoud A. Pouladi, PhD Our current understanding of the pathological processes underlying HD has benefited immensely from a large number of animal models developed throughout the past two decades. The establishment of such models was facilitated by refinements in transgenic technologies such as yeast and bacterial
+ Read More

HD Insights Volume 8 (PDF)

October 23rd, 2013 Heather Hare